DOCSLIB.ORG

SRSF6 (NM 006275) Human Untagged Clone – SC125351 | Origene

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SRSF6 (NM 006275) Human Untagged Clone – SC125351 | Origene OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for SC125351 SRSF6 (NM_006275) Human Untagged Clone Product data: Product Type: Expression Plasmids Product Name: SRSF6 (NM_006275) Human Untagged Clone Tag: Tag Free Symbol: SRSF6 Synonyms: B52; HEL-S-91; SFRS6; SRP55 Vector: pCMV6-XL5 E. coli Selection: Ampicillin (100 ug/mL) Cell Selection: None Fully Sequenced ORF: >OriGene ORF within SC125351 sequence for NM_006275 edited (data generated by NextGen Sequencing) ATGCCGCGCGTCTACATAGGACGCCTGAGCTACAACGTCCGGGAGAAGGACATCCAGCGC TTTTTCAGTGGCTATGGCCGCCTCCTCGAAGTAGACCTCAAAAATGGGTACGGCTTCGTG GAGTTCGAGGACTCCCGCGACGCCGACGACGCCGTTTACGAGCTGAACGGCAAGGAGCTC TGCGGCGAGCGCGTGATCGTAGAGCACGCCCGGGGCCCGCGTCGCGATCGCGACGGCTAC AGCTACGGAAGCCGCAGTGGTGGAGGTGGATACAGCAGTCGGAGAACATCTGGCAGAGAC AAATACGGACCACCTGTTCGTACAGAATACAGGCTTATTGTAGAAAATCTTTCTAGTCGG TGCAGTTGGCAAGATTTAAAGGATTTTATGCGACAAGCAGGTGAAGTAACCTATGCGGAT GCCCACAAGGAACGAACAAATGAGGGTGTAATTGAGTTTCGCTCCTACTCTGACATGAAG CGTGCTTTGGACAAACTGGATGGCACAGAAATAAATGGCAGAAATATTAGGCTTATTGAA GATAAGCCACGCACAAGCCATAGGCGATCTTACTCTGGAAGCAGATCCAGGTCTCGATCT AGAAGACGGTCACGAAGTAGGAGTCGCAGGAGCAGCCGCAGTAGATCTCGAAGTATCTCA AAAAGTCGCTCCCGTTCCAGGTCGCGGAGCAAAGGTCGATCACGTTCTCGATCAAAAGGC AGGAAATCTAGATCAAAGAGCAAATCTAAGCCCAAGTCTGATCGGGGCTCCCATTCACAT TCTCGAAGCAGATCTAAGGATGAGTATGAGAAATCTCGAAGCAGGTCTCGGTCCCGATCC CCCAAAGAAAATGGAAAGGGTGATATAAAGTCAAAATCCAGATCAAGGAGCCAGTCCCGT TCCAATTCGCCGCTACCTGTTCCACCCTCAAAGGCCCGTTCTGTGTCCCCTCCACCAAAA AGAGCTACTTCAAGATCCCGTTCTAGATCTCGCTCAAAGTCAAGATCAAGGTCCAGGTCG AGTTCCAGAGATTAA Clone variation with respect to NM_006275.5 843 t=>c This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 3 SRSF6 (NM_006275) Human Untagged Clone – SC125351 5' Read Nucleotide >OriGene 5' read for NM_006275 unedited Sequence: CACGACTTACTATAGGCGGCCGCGATTCGGCACGAGGCCCGCCACGGACATGCCGCGCGT CTACATAGGACGCCTGAGCTACAACGTCCGGGAGAAGGACATCCAGCGCTTTTTCAGTGG CTATGGCCGCCTCCTCGAAGTAGACCTCAAAAATGGGTACGGCTTCGTGGAGTTCGAGGA CTCCCGCGACGCCGACGACGCCGTTTACGAGCTGAACGGCAAGGAGCTCTGCGGCGAGCG CGTGATCGTAGAGCACGCCCGGGGCCCGCGTCGCGATCGCGACGGCTACAGCTACGGAAG CCGCAGTGGTGGAGGTGGATACAGCAGTCGGAGAACATCTGGCAGAGACAAATACGGACC ACCTGTTCGTACAGAATACAGGCTTATTGTAGAAAATCTTTCTAGTCGGTGCAGTTGGCA AGATTTAAAGGATTTTATGCGACAAGCAGGTGAAGTAACCTATGCGGATGCCCACAAGGA ACGAACAAATGAGGGTGTAATTGAGTTTCGCTCCTACTCTGACATGAAGCGTGCTTTGGA CAAACTGGATGGCACAGAAATAAATGGCAGAAATATTAGGCTTATTGAAGATAAGCCACG CACAAGCNCATAGGCGATCTTACTCTGGAAGCAGATCCAGGTNCTCGATCTAGAAGACGG TCACGAAGTANGAGTCGCAGGAGCAGCCGCAGTAGATCTCGAAGTATCTCAAAAAGTCGC TCCCGTTCCAGGTCGCGGAGCAAAGGGTCGATCACGNTTCTCGATCAAAAGGCAGGGAAA TCTAGATCAAAGAGCANATCTAAGCCCAAGTCTGATCGGGGCTCCCATTCACATTCTCGA AGCAGATCTAGGGATGAGTATGAGAAATCTCGAGCAGTCTCGTTCCCGATCCCCAAAGAA TGGNANGGNTGATATAAGTCAAATCAATCANGAGCCAGTCCCGTCAATCGCGCTACTGTC ACCTCAAGCCCCGTTCTGG 3' Read Nucleotide >OriGene 3' read for NM_006275 unedited Sequence: GTGGCATGGCATGGCAACTTCCAGGGCCAGGAAGGCACTGGGGNGGGGTCACAGGGCAGC CACCCGGGTATCTGTTCAGGAAAACAGCTATGACCGCGGCCGCAATCTAGAGTCGAGTTT TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTC CCCCCCAGAAAGTTTTTTATGGGGATTAAAAGCACAAAATGGGGGAACAAATGGGGGGGG GGGGGGAAACACGGGGGGGGGAACGTAAAAGTCAAAGGGGGGGGGACTCAAACGGGCCAA AAGGGCCCTAGGGGGTGTTCATAAACCAGCTCAAGTAAAAGAAGGGGGAAACAAGAGGTT CTCACTTTTTTTCGGCCCCACCTTAATACTCCATCTAGCCACGGGTAGGGGGCATGTCAT CAACTTATTCTTCTCACAGGCTAGGGGGGGAATTAAACATTTTATCAGTCAACCCTATGC TCACCAAGGGGGCCAATGTTACACAGTGTTTTTGGGCATCCGGGGACTGAAAACTACGGG GAAGGATGGGCCCTGACTGAAAATAAATGGGGCGGGGCTATAAATAAAAAATTGGGGGGG CGGGCGTTTACCTAAACAAGGACCGGGTTAAGGGGGGAACAAAAATTTGAGCAAAACCGT CTATTACCAAGGGAGGTCCTAATAAAAAGAAGACCCCGGTGGGAGGGGGGTTTCAAACCT TTAAAAAAGGCCTATTTTTTTGGTGGAAATACCCCCCCCCCCCCCTTTTAAAAAAGGGGG GGGGAAAAAAAAGGACTTTTGTGTTTTTTTCCCGAGAAAAAAGAAAATTGGGGGAAAGCC CATTTTTAAAAGTCCTCCCCTCGGGGTGGGGGGCCAAAAATTGTTACTTTAACACCGACC TTTTTTTTTGTTTTTT Restriction Sites: NotI-NotI ACCN: NM_006275 Insert Size: 4200 bp OTI Disclaimer: Our molecular clone sequence data has been matched to the reference identifier above as a point of reference. Note that the complete sequence of our molecular clones may differ from the sequence published for this corresponding reference, e.g., by representing an alternative RNA splicing form or single nucleotide polymorphism (SNP). RefSeq: NM_006275.4, NP_006266.2 RefSeq Size: 3738 bp RefSeq ORF: 1035 bp Locus ID: 6431 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 2 / 3 SRSF6 (NM_006275) Human Untagged Clone – SC125351 UniProt ID: Q13247 Domains: RRM Protein Pathways: Spliceosome Gene Summary: The protein encoded by this gene is involved in mRNA splicing and may play a role in the determination of alternative splicing. The encoded nuclear protein belongs to the splicing factor SR family and has been shown to bind with and modulate another member of the family, SFRS12. Alternative splicing results in multiple transcript variants. In addition, two pseudogenes, one on chromosome 17 and the other on the X chromosome, have been found for this gene.[provided by RefSeq, Sep 2010] Transcript Variant: This variant (1) represents the shorter, protein-coding transcript. This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 3 / 3.
Load more

Recommended publications
  • Cooperativity of Imprinted Genes Inactivated by Acquired Chromosome 20Q Deletions
    Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions Athar Aziz, … , Anne C. Ferguson-Smith, Anthony R. Green J Clin Invest. 2013;123(5):2169-2182. https://doi.org/10.1172/JCI66113. Research Article Oncology Large regions of recurrent genomic loss are common in cancers; however, with a few well-characterized exceptions, how they contribute to tumor pathogenesis remains largely obscure. Here we identified primate-restricted imprinting of a gene cluster on chromosome 20 in the region commonly deleted in chronic myeloid malignancies. We showed that a single heterozygous 20q deletion consistently resulted in the complete loss of expression of the imprinted genes L3MBTL1 and SGK2, indicative of a pathogenetic role for loss of the active paternally inherited locus. Concomitant loss of both L3MBTL1 and SGK2 dysregulated erythropoiesis and megakaryopoiesis, 2 lineages commonly affected in chronic myeloid malignancies, with distinct consequences in each lineage. We demonstrated that L3MBTL1 and SGK2 collaborated in the transcriptional regulation of MYC by influencing different aspects of chromatin structure. L3MBTL1 is known to regulate nucleosomal compaction, and we here showed that SGK2 inactivated BRG1, a key ATP-dependent helicase within the SWI/SNF complex that regulates nucleosomal positioning. These results demonstrate a link between an imprinted gene cluster and malignancy, reveal a new pathogenetic mechanism associated with acquired regions of genomic loss, and underline the complex molecular and cellular consequences of “simple” cancer-associated chromosome deletions. Find the latest version: https://jci.me/66113/pdf Research article Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions Athar Aziz,1,2 E. Joanna Baxter,1,2,3 Carol Edwards,4 Clara Yujing Cheong,5 Mitsuteru Ito,4 Anthony Bench,3 Rebecca Kelley,1,2 Yvonne Silber,1,2 Philip A.
    [Show full text]
  • 1 Inventory of Supplemental Information Presented in Relation To
    Inventory of Supplemental Information presented in relation to each of the main figures in the manuscript 1. Figure S1. Related to Figure 1. 2. Figure S2. Related to Figure 2. 3. Figure S3. Related to Figure 3. 4. Figure S4. Related to Figure 4. 5. Figure S5. Related to Figure 5. 6. Figure S6. Related to Figure 6. 7. Figure S7. Related to Figure 7. 8. Table S1. Related to Figures 1 and S1. 9. Table S2. Related to Figures 3, 4, 6 and 7. 10. Table S3. Related to Figure 3. Supplemental Experimental Procedures 1. Patients and samples 2. Cell culture 3. Long term culture-initiating cells (LTC-IC) assay 4. Differentiation of CD34+ cord blood cells 5. Bi-phasic erythroid differentiation assay 6. Clonal assay 7. Mutation and sequencing analysis 8. Bisulphite sequencing and quantitative pyrosequencing 9. Human SNP genotyping 10. Strand-specific cDNA synthesis and PCR 11. Chromatin Immuno-precipitation (ChIP) 12. Immunoprecipitation and western blot 13. Colony genotyping 14. shRNA generation and viral infection 15. Retrovirus generation and transduction 16. Study approval 17. Statistical Methods 18. Primers list Supplementary References (19) 1 Additional SGK2 families 2 3 4 ♂ ♀ ♂ ♀ ♂ ♀ C/G C/C C/C C/G C/C C/G ♀ ♀ ♂ ♀ C/G C/G C/G C/G T T C T G C T A G A T T C T C C T A G A T T C T C C T A G A T T C T C C T A G A T-Cells T-Cells T-Cells T-Cells Additional GDAP1L1 familiy 2 ♂ ♀ G/G A/A ♀ G/A A C A C G G T G Erythroblasts Figure S1 - .
    [Show full text]
  • Aneuploidy: Using Genetic Instability to Preserve a Haploid Genome?
    Health Science Campus FINAL APPROVAL OF DISSERTATION Doctor of Philosophy in Biomedical Science (Cancer Biology) Aneuploidy: Using genetic instability to preserve a haploid genome? Submitted by: Ramona Ramdath In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Science Examination Committee Signature/Date Major Advisor: David Allison, M.D., Ph.D. Academic James Trempe, Ph.D. Advisory Committee: David Giovanucci, Ph.D. Randall Ruch, Ph.D. Ronald Mellgren, Ph.D. Senior Associate Dean College of Graduate Studies Michael S. Bisesi, Ph.D. Date of Defense: April 10, 2009 Aneuploidy: Using genetic instability to preserve a haploid genome? Ramona Ramdath University of Toledo, Health Science Campus 2009 Dedication I dedicate this dissertation to my grandfather who died of lung cancer two years ago, but who always instilled in us the value and importance of education. And to my mom and sister, both of whom have been pillars of support and stimulating conversations. To my sister, Rehanna, especially- I hope this inspires you to achieve all that you want to in life, academically and otherwise. ii Acknowledgements As we go through these academic journeys, there are so many along the way that make an impact not only on our work, but on our lives as well, and I would like to say a heartfelt thank you to all of those people: My Committee members- Dr. James Trempe, Dr. David Giovanucchi, Dr. Ronald Mellgren and Dr. Randall Ruch for their guidance, suggestions, support and confidence in me. My major advisor- Dr. David Allison, for his constructive criticism and positive reinforcement.
    [Show full text]
  • Análise Correlacional Entre a Expressão Dos Fatores De Splicing E a Ocorrência De Splicing Alternativo Em Tecidos Humanos E De Camundongos
    ANÁLISE CORRELACIONAL ENTRE A EXPRESSÃO DOS FATORES DE SPLICING E A OCORRÊNCIA DE SPLICING ALTERNATIVO EM TECIDOS HUMANOS E DE CAMUNDONGOS JULIO CÉSAR NUNES Dissertação apresentada à Fundação Antônio Prudente para a obtenção do título de Mestre em Ciências Área de Concentração: Oncologia Orientador: Dr. Sandro José de Souza São Paulo 2008 Livros Grátis http://www.livrosgratis.com.br Milhares de livros grátis para download. FICHA CATALOGRÁFICA Preparada pela Biblioteca da Fundação Antônio Prudente Nunes, Julio César Análise correlacional entre a expressão dos fatores de splicing e a ocorrência de splicing alternativo em tecidos humanos e de camundongos / Julio César Nunes – São Paulo, 2008. 79p. Dissertação (Mestrado) - Fundação Antônio Prudente. Curso de Pós-Graduação em Ciências - Área de concentração: Oncologia. Orientador: Sandro José Souza Descritores: 1. SPLICING ALTERNATIVO 2. BIOLOGIA MOLECULAR COMPUTACIONAL 3. CÂNCER 4. GENOMICA. AGRADECIMENTOS Agradeço à FAPESP e CAPES pela bolsa de Mestrado. Ao Sandro José de Souza agradeço toda orientação e conhecimento oferecido. Meus especiais agradecimentos ao Pedro Alexandre Favoretto Galante que dedicou atenção a minha formação no processo de Pós-Graduação na Fundação Antônio Prudente, bem como pela sua oficiosa co-orientação ao projeto de pesquisa. À grande família e amigos pela dedicação e incentivo a minha formação acadêmica. À Fundação Antônio Prudente, Hospital do Câncer e Instituto Ludwig de Pesquisa sobre o Câncer dedico os meus nobres agradecimentos finais. RESUMO Nunes JC. Análise correlacional entre a expressão dos fatores de splicing e a ocorrência de splicing alternativo em tecidos humanos e de camundongos. São Paulo; 2007. [Dissertacão de Mestrado - Fundação Antônio Prudente] Splicing alternativo desempenha uma significante função no aumento da complexidade genômica, produzindo um extenso número de mRNA e isoformas protéicas.
    [Show full text]
  • Expression Analysis of Genes Located Within the Common Deleted Region
    Leukemia Research 84 (2019) 106175 Contents lists available at ScienceDirect Leukemia Research journal homepage: www.elsevier.com/locate/leukres Research paper Expression analysis of genes located within the common deleted region of del(20q) in patients with myelodysplastic syndromes T ⁎ Masayuki Shiseki , Mayuko Ishii, Michiko Okada, Mari Ohwashi, Yan-Hua Wang, Satoko Osanai, Kentaro Yoshinaga, Naoki Mori, Toshiko Motoji, Junji Tanaka Department of Hematology, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan ARTICLE INFO ABSTRACT Keywords: Deletion of the long arm of chromosome 20 (del(20q)) is observed in 5–10% of patients with myelodysplastic Deletion 20q syndromes (MDS). We examined the expression of 28 genes within the common deleted region (CDR) of del Common deleted region (20q), which we previously determined by a CGH array using clinical samples, in 48 MDS patients with (n = 28) Myelodysplastic syndromes or without (n = 20) chromosome 20 abnormalities and control subjects (n = 10). The expression level of 8 of 28 genes was significantly reduced in MDS patients with chromosome 20 abnormalities compared to that of control subjects. In addition, the expression of BCAS4, ADA, and YWHAB genes was significantly reduced in MDS pa- tients without chromosome 20 abnormalities, which suggests that these three genes were commonly involved in the molecular pathogenesis of MDS. To evaluate the clinical significance, we analyzed the impact of the ex- pression level of each gene on overall survival (OS). According to the Cox proportional hazard model, multi- variate analysis indicated that reduced BCAS4 expression was associated with inferior OS, but the difference was not significant (HR, 3.77; 95% CI, 0.995-17.17; P = 0.0509).
    [Show full text]
  • Supporting Information
    Supporting Information Whittle et al. 10.1073/pnas.0812894106 SI Text range based on analysis on 1.5% agarose gels after reversal of In Vitro Genomic Selection. Recombinant NFI-1-GST fusion pro- cross-linking. DNA-protein complexes were precipitated with tein was immobilized on Glutathione Sepharose 4B (Amersham) anti-NFI immune serum (5 ␮l) or preimmune serum (5 ␮l) as a and C. elegans genomic DNA was used for in vitro genomic control and 5% of the input sample was set aside. Samples were selection. The fusion protein contained the NFI-1 DNA-binding processed using the ChIP assay kit (Upstate). Following reversal domain and a short downstream region. For NFI-1-GST Sepha- of the cross-links, RNase A and Proteinase K treatments, the rose preparation, 400 ml of induced DH5␣ cells expressing immunoprecipitated DNA was purified using phenol-chloro- NFI-1-GST (plasmid pGEXNFI-1) was extracted in buffer L (25 form, precipitated with ethanol, and dissolved in 50 ␮l of DNase, mM Hepes pH 7.5, 10% sucrose, 0.35 M NaCl, 5 mM DTT, 1 mM Rnase-free water. For ChIP-chip, samples were amplified by PMSF, 0.1% Nonidet P-40 and 2 mg/ml of lysozyme). The extract either ligation mediated PCR (5) or a modified Whole Genome (35 ml) was flash-frozen in 5-ml aliquots and stored at –70 °C. To Amplification protocol [Sigma; (6)] as previously described. immobilize NFI-1-GST protein on Glutathione Sepharose 4B, 5 ml of cell extract was incubated with 65 ␮l (bed volume) of Microarrays and Data Extraction.
    [Show full text]
  • Mai Muudatuntuu Ti on Man Mini
    MAIMUUDATUNTUU US009809854B2 TI ON MAN MINI (12 ) United States Patent ( 10 ) Patent No. : US 9 ,809 ,854 B2 Crow et al. (45 ) Date of Patent : Nov . 7 , 2017 Whitehead et al. (2005 ) Variation in tissue - specific gene expression ( 54 ) BIOMARKERS FOR DISEASE ACTIVITY among natural populations. Genome Biology, 6 :R13 . * AND CLINICAL MANIFESTATIONS Villanueva et al. ( 2011 ) Netting Neutrophils Induce Endothelial SYSTEMIC LUPUS ERYTHEMATOSUS Damage , Infiltrate Tissues, and Expose Immunostimulatory Mol ecules in Systemic Lupus Erythematosus . The Journal of Immunol @(71 ) Applicant: NEW YORK SOCIETY FOR THE ogy , 187 : 538 - 552 . * RUPTURED AND CRIPPLED Bijl et al. (2001 ) Fas expression on peripheral blood lymphocytes in MAINTAINING THE HOSPITAL , systemic lupus erythematosus ( SLE ) : relation to lymphocyte acti vation and disease activity . Lupus, 10 :866 - 872 . * New York , NY (US ) Crow et al . (2003 ) Microarray analysis of gene expression in lupus. Arthritis Research and Therapy , 5 :279 - 287 . * @(72 ) Inventors : Mary K . Crow , New York , NY (US ) ; Baechler et al . ( 2003 ) Interferon - inducible gene expression signa Mikhail Olferiev , Mount Kisco , NY ture in peripheral blood cells of patients with severe lupus . PNAS , (US ) 100 ( 5 ) : 2610 - 2615. * GeneCards database entry for IFIT3 ( obtained from < http : / /www . ( 73 ) Assignee : NEW YORK SOCIETY FOR THE genecards. org /cgi - bin / carddisp .pl ? gene = IFIT3 > on May 26 , 2016 , RUPTURED AND CRIPPLED 15 pages ) . * Navarra et al. (2011 ) Efficacy and safety of belimumab in patients MAINTAINING THE HOSPITAL with active systemic lupus erythematosus : a randomised , placebo FOR SPECIAL SURGERY , New controlled , phase 3 trial . The Lancet , 377 :721 - 731. * York , NY (US ) Abramson et al . ( 1983 ) Arthritis Rheum .
    [Show full text]
  • Drosophila and Human Transcriptomic Data Mining Provides Evidence for Therapeutic
    Drosophila and human transcriptomic data mining provides evidence for therapeutic mechanism of pentylenetetrazole in Down syndrome Author Abhay Sharma Institute of Genomics and Integrative Biology Council of Scientific and Industrial Research Delhi University Campus, Mall Road Delhi 110007, India Tel: +91-11-27666156, Fax: +91-11-27662407 Email: [email protected] Nature Precedings : hdl:10101/npre.2010.4330.1 Posted 5 Apr 2010 Running head: Pentylenetetrazole mechanism in Down syndrome 1 Abstract Pentylenetetrazole (PTZ) has recently been found to ameliorate cognitive impairment in rodent models of Down syndrome (DS). The mechanism underlying PTZ’s therapeutic effect is however not clear. Microarray profiling has previously reported differential expression of genes in DS. No mammalian transcriptomic data on PTZ treatment however exists. Nevertheless, a Drosophila model inspired by rodent models of PTZ induced kindling plasticity has recently been described. Microarray profiling has shown PTZ’s downregulatory effect on gene expression in fly heads. In a comparative transcriptomics approach, I have analyzed the available microarray data in order to identify potential mechanism of PTZ action in DS. I find that transcriptomic correlates of chronic PTZ in Drosophila and DS counteract each other. A significant enrichment is observed between PTZ downregulated and DS upregulated genes, and a significant depletion between PTZ downregulated and DS dowwnregulated genes. Further, the common genes in PTZ Nature Precedings : hdl:10101/npre.2010.4330.1 Posted 5 Apr 2010 downregulated and DS upregulated sets show enrichment for MAP kinase pathway. My analysis suggests that downregulation of MAP kinase pathway may mediate therapeutic effect of PTZ in DS. Existing evidence implicating MAP kinase pathway in DS supports this observation.
    [Show full text]
  • Ultraconserved Elements Are Associated with Homeostatic Control of Splicing Regulators by Alternative Splicing and Nonsense-Mediated Decay
    Downloaded from genesdev.cshlp.org on September 24, 2021 - Published by Cold Spring Harbor Laboratory Press Ultraconserved elements are associated with homeostatic control of splicing regulators by alternative splicing and nonsense-mediated decay Julie Z. Ni,1 Leslie Grate,1 John Paul Donohue,1 Christine Preston,2 Naomi Nobida,2 Georgeann O’Brien,2 Lily Shiue,1 Tyson A. Clark,3 John E. Blume,3 and Manuel Ares Jr.1,2,4 1Center for Molecular Biology of RNA and Department of Molecular, Cell, and Developmental Biology, University of California at Santa Cruz, Santa Cruz, California 95064, USA; 2Hughes Undergraduate Research Laboratory, University of California at Santa Cruz, Santa Cruz, California 95064, USA; 3Affymetrix, Inc., Santa Clara, California 95051, USA Many alternative splicing events create RNAs with premature stop codons, suggesting that alternative splicing coupled with nonsense-mediated decay (AS-NMD) may regulate gene expression post-transcriptionally. We tested this idea in mice by blocking NMD and measuring changes in isoform representation using splicing-sensitive microarrays. We found a striking class of highly conserved stop codon-containing exons whose inclusion renders the transcript sensitive to NMD. A genomic search for additional examples identified >50 such exons in genes with a variety of functions. These exons are unusually frequent in genes that encode splicing activators and are unexpectedly enriched in the so-called “ultraconserved” elements in the mammalian lineage. Further analysis show that NMD of mRNAs for splicing activators such as SR proteins is triggered by splicing activation events, whereas NMD of the mRNAs for negatively acting hnRNP proteins is triggered by splicing repression, a polarity consistent with widespread homeostatic control of splicing regulator gene expression.
    [Show full text]
  • 1471-2105-8-217.Pdf
    BMC Bioinformatics BioMed Central Software Open Access GenMAPP 2: new features and resources for pathway analysis Nathan Salomonis1,2, Kristina Hanspers1, Alexander C Zambon1, Karen Vranizan1,3, Steven C Lawlor1, Kam D Dahlquist4, Scott W Doniger5, Josh Stuart6, Bruce R Conklin1,2,7,8 and Alexander R Pico*1 Address: 1Gladstone Institute of Cardiovascular Disease, 1650 Owens Street, San Francisco, CA 94158 USA, 2Pharmaceutical Sciences and Pharmacogenomics Graduate Program, University of California, 513 Parnassus Avenue, San Francisco, CA 94143, USA, 3Functional Genomics Laboratory, University of California, Berkeley, CA 94720 USA, 4Department of Biology, Loyola Marymount University, 1 LMU Drive, MS 8220, Los Angeles, CA 90045 USA, 5Computational Biology Graduate Program, Washington University School of Medicine, St. Louis, MO 63108 USA, 6Department of Biomolecular Engineering, University of California, Santa Cruz, CA 95064 USA, 7Department of Medicine, University of California, San Francisco, CA 94143 USA and 8Department of Molecular and Cellular Pharmacology, University of California, San Francisco, CA 94143 USA Email: Nathan Salomonis - [email protected]; Kristina Hanspers - [email protected]; Alexander C Zambon - [email protected]; Karen Vranizan - [email protected]; Steven C Lawlor - [email protected]; Kam D Dahlquist - [email protected]; Scott W Doniger - [email protected]; Josh Stuart - [email protected]; Bruce R Conklin - [email protected]; Alexander R Pico* - [email protected] * Corresponding author Published: 24 June 2007 Received: 16 November 2006 Accepted: 24 June 2007 BMC Bioinformatics 2007, 8:217 doi:10.1186/1471-2105-8-217 This article is available from: http://www.biomedcentral.com/1471-2105/8/217 © 2007 Salomonis et al; licensee BioMed Central Ltd.
    [Show full text]
  • 1 Title: Ultra-Conserved Elements in the Human Genome Authors And
    4/22/2004 Title: Ultra-conserved elements in the human genome Authors and affiliations: Gill Bejerano*, Michael Pheasant**, Igor Makunin**, Stuart Stephen**, W. James Kent*, John S. Mattick** and David Haussler*** *Department of Biomolecular Engineering and ***Howard Hughes Medical Institute, University of California Santa Cruz, Santa Cruz, CA 95064, USA **ARC Special Research Centre for Functional and Applied Genomics, Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD 4072, Australia Corresponding authors: Gill Bejerano ([email protected]) and David Haussler ([email protected]) -------------------------------------------------------------------------------------------------------------------- Supporting on-line material: Separate figures, Like Figure 1 but for each individual chromosome are available in postscript and PDF format, at http://www.cse.ucsc.edu/~jill/ultra.html. Table S1. A table listing all 481 ultra conserved elements and their properties can be found at http://www.cse.ucsc.edu/~jill/ultra.html. The elements were extracted from an alignment of NCBI Build 34 of the human genome (July 2003, UCSC hg16), mouse NCBI Build 30 (February 2003, UCSC mm3), and rat Baylor HGSC v3.1 (June 2003, UCSC rn3). This table does not include an additional, probably ultra conserved element (uc.10) overlapping an alternatively spliced exon of FUSIP1, which is not yet placed in the current assembly of human chromosome 1. Nor does the list contain the ultra conserved elements found in ribosomal RNA sequences, as these are not currently present as part of the draft genome sequences. The small subunit 18S rRNA includes 3 ultra conserved regions of sizes 399, 224, 212bp and the large subunit 28S rRNA contains 3 additional regions of sizes 277, 335, 227bp (the later two are one base apart).
    [Show full text]
  • The DNA Sequence and Comparative Analysis of Human Chromosome 20
    articles The DNA sequence and comparative analysis of human chromosome 20 P. Deloukas, L. H. Matthews, J. Ashurst, J. Burton, J. G. R. Gilbert, M. Jones, G. Stavrides, J. P. Almeida, A. K. Babbage, C. L. Bagguley, J. Bailey, K. F. Barlow, K. N. Bates, L. M. Beard, D. M. Beare, O. P. Beasley, C. P. Bird, S. E. Blakey, A. M. Bridgeman, A. J. Brown, D. Buck, W. Burrill, A. P. Butler, C. Carder, N. P. Carter, J. C. Chapman, M. Clamp, G. Clark, L. N. Clark, S. Y. Clark, C. M. Clee, S. Clegg, V. E. Cobley, R. E. Collier, R. Connor, N. R. Corby, A. Coulson, G. J. Coville, R. Deadman, P. Dhami, M. Dunn, A. G. Ellington, J. A. Frankland, A. Fraser, L. French, P. Garner, D. V. Grafham, C. Grif®ths, M. N. D. Grif®ths, R. Gwilliam, R. E. Hall, S. Hammond, J. L. Harley, P. D. Heath, S. Ho, J. L. Holden, P. J. Howden, E. Huckle, A. R. Hunt, S. E. Hunt, K. Jekosch, C. M. Johnson, D. Johnson, M. P. Kay, A. M. Kimberley, A. King, A. Knights, G. K. Laird, S. Lawlor, M. H. Lehvaslaiho, M. Leversha, C. Lloyd, D. M. Lloyd, J. D. Lovell, V. L. Marsh, S. L. Martin, L. J. McConnachie, K. McLay, A. A. McMurray, S. Milne, D. Mistry, M. J. F. Moore, J. C. Mullikin, T. Nickerson, K. Oliver, A. Parker, R. Patel, T. A. V. Pearce, A. I. Peck, B. J. C. T. Phillimore, S. R. Prathalingam, R. W. Plumb, H. Ramsay, C. M.
    [Show full text]